Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database

Abstract Congenital anomalies of the external ear can have a significant impact on a child’s development and quality of life. While genetic factors play a crucial role in the etiology of these anomalies, environmental factors such as drug exposure during pregnancy may also contribute to their occurr...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Xinyu Li, Jiajia Hao, Datao Li, Ruhong Zhang
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-10-01
Subjects:	Congenital anomalies FAERS Disproportionality analysis Pharmacovigilance
Online Access:	https://doi.org/10.1038/s41598-024-74744-3

Similar Items

Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
by: Dan Xu, et al.
Published: (2024-10-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Dao-chun Xiang, et al.
Published: (2024-09-01)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023-01-01)

Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS
by: Que H, et al.
Published: (2025-10-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system
by: Fengfen Liu, et al.
Published: (2025-03-01)

Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Wen-Long Xie, et al.
Published: (2024-10-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
by: Lisha Wu, et al.
Published: (2024-08-01)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
by: Ye Hu, et al.
Published: (2025-02-01)

Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024-05-01)

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2024-06-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database
by: Jintuo Zhou, et al.
Published: (2025-09-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration
by: Jing Zhang, et al.
Published: (2024-10-01)

Assessment of drug-related migraine in a real-world large-scale database
by: Fan Wu, et al.
Published: (2025-07-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
by: Yongli Hu, et al.
Published: (2024-07-01)

Arrhythmic events pertinent with antidepressants: a Bayesian disproportional analysis mining the FDA Adverse Event Reporting System database
by: Shan Cao, et al.
Published: (2025-09-01)

Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database
by: Lingli Huang, et al.
Published: (2025-09-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
by: Zhiwen Fu, et al.
Published: (2024-06-01)

Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin
by: Zhi Wang, et al.
Published: (2025-05-01)

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
by: Fang Wu, et al.
Published: (2025-02-01)

Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
by: Mengjiao He, et al.
Published: (2025-02-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Drug-induced Sweet’s syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression
by: Yuhan Xie, et al.
Published: (2025-09-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)